Selank vs Semax
Last updated: 2026-06-22
- Selank is derived from the immunomodulatory peptide tuftsin; Semax is derived from ACTH (adrenocorticotropic hormone).
- Selank research focuses on anxiolytic and immune-modulatory effects; Semax research emphasizes cognitive enhancement and neuroprotection.
- Both were developed at the Institute of Molecular Genetics in Russia and have regulatory approval there as nasal sprays.
- Selank modulates GABA and serotonin systems; Semax primarily influences BDNF and melanocortin pathways.
- Both have relatively favorable safety profiles in available studies.
Selank and Semax are both Russian-developed neuropeptides, but Selank is primarily studied for anxiety modulation while Semax is studied for cognitive enhancement and neuroprotection.
Side-by-Side Comparison
| Attribute | Selank | Semax |
|---|---|---|
| What It Is | A synthetic peptide analog of tuftsin studied for anxiolytic and nootropic properties. | A synthetic peptide derived from ACTH, studied for cognitive enhancement and neuroprotective effects. |
| Typical Research Focus | ||
| Proposed Mechanisms | Not yet documented | Not yet documented |
| Evidence Snapshot |
Medium Evidenceprescription drug
|
Medium Evidenceprescription drug
|
| Cautions |
|
|
Selank
- What It Is
- A synthetic peptide analog of tuftsin studied for anxiolytic and nootropic properties.
- Research Focus
- Evidence
- Medium Evidence
- Cautions
-
- Approved in Russia but not FDA-approved in the US
- Most research published in Russian-language journals
- Long-term Western clinical data limited
Semax
- What It Is
- A synthetic peptide derived from ACTH, studied for cognitive enhancement and neuroprotective effects.
- Research Focus
- Evidence
- Medium Evidence
- Cautions
-
- Approved in Russia/Ukraine but not FDA-approved
- PCAC review scheduled July 24, 2026 for potential 503A Bulks List addition; proposed indications include cerebral ischemia, migraine, and trigeminal neuralgia
- Western clinical trial data is limited
When Researchers Compare Them
Selank and Semax are often compared because both originate from the same Russian research institution and are among the few peptides with regulatory approval (in Russia) for neurological applications. Despite this shared background, their mechanisms and primary research applications diverge.
Selank, a synthetic analog of the immunopeptide tuftsin, has been studied for its effects on the GABAergic and serotonergic systems. Research has explored its potential anxiolytic properties and immune-modulatory effects without the sedation typically associated with benzodiazepines.
Semax, derived from a fragment of ACTH (4-10), has been investigated for cognitive enhancement and neuroprotection. Studies suggest it may increase brain-derived neurotrophic factor (BDNF) levels and modulate melanocortin receptors. Research has examined its potential role in stroke recovery, cognitive decline, and attention disorders.
Peptide Profiles
Citations
Explore Research Tools
Use calculators for reconstitution, dosing references, and more.
Use PepTracker Pro ToolsRelated Peptides
Cerebrolysin
Medium EvidenceA porcine brain-derived peptide mixture approved in some countries for stroke recovery and neurodegenerative conditions.
Davunetide
Low EvidenceAn eight-amino-acid ADNP-derived peptide studied for microtubule stabilization, tau-related neuroprotection, and rare ADNP syndrome.
Dihexa
Low EvidenceA hexapeptide analog studied for cognitive enhancement via hepatocyte growth factor pathway activation.
DSIP
Low EvidenceA neuropeptide studied for its role in sleep regulation and stress modulation.
P21
Medium EvidenceAn 11-amino-acid CNTF-derived peptide studied for its ability to upregulate BDNF expression and promote neurogenesis in cognitive decline models.
Trontinemab
Medium EvidenceAn investigational, brain-penetrant anti-amyloid antibody from Roche/Genentech that uses the proprietary 'Brainshuttle' transferrin-receptor delivery system to reach the brain far more efficiently than conventional antibodies. Trontinemab (development codes RG6102 / RO7126209) is a 2+1 bispecific molecule: it fuses the amyloid-beta-clearing antibody gantenerumab to a fragment that grabs transferrin receptor 1 (TfR1) on blood-brain-barrier cells, hitching a ride into the brain via the same receptor-mediated transport that carries iron. That shuttle lets a low intravenous dose clear amyloid plaques rapidly and deeply while triggering strikingly little of the brain swelling and micro-bleeding (ARIA) that limits approved anti-amyloid drugs. In the Phase Ib/IIa Brainshuttle AD study (NCT04639050), the 3.6 mg/kg dose removed roughly 107 centiloids of amyloid after 28 weeks, driving about 91-92% of participants below the amyloid-positivity threshold (24 centiloids) - with ARIA-E seen in fewer than 5% of participants, well below the ~13% reported for lecanemab and ~24% for donanemab. On the strength of those data, Roche launched two identical pivotal Phase 3 trials - TRONTIER 1 and TRONTIER 2 - in early symptomatic Alzheimer's disease (about 1,600 patients across 18 countries, begun in 2025), and at the 2026 Alzheimer's Association International Conference (AAIC) in London it unveiled PrevenTRON, a Phase 3 prevention trial in 1,600 cognitively unimpaired people at high risk (elevated plasma p-tau217). Trontinemab is a prescription-stage investigational biologic - it is not approved anywhere and is not a supplement or research chemical.